All In Biotech

Drug Trial Radar · NCT01876628

Adjunctive Clindamycin for Cellulitis: C4C Trial.

A Double Blind Randomised Control Trial to Measure the Effect of the Addition of Clindamycin to Flucloxacillin for the Treatment of Limb Cellulitis

Last checked: Nov 19, 2026Latest source record: Aug 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

410

Actual

Start

Oct 2013

Primary completion

Dec 2015

Study completion Mar 2016

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
University of Bristol; Public Health England
First posted
Jun 12, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to see whether the addition of Clindamycin, a protein inhibiting antibiotic, to the standard antibiotic treatment of limb cellulitis, with Flucloxacillin, results in less tissue damage and a more rapid resolution of both systemic and local features, in a cost-effective manner. This study is a randomised controlled trial comparing Clindamycin with placebo.

Conditions

  • Cellulitis

Interventions

  • FlucloxacillinDrug

    Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.

  • ClindamycinDrug

    Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.

  • Placebo oral capsuleDrug

    Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement based on a composite of systemic and local featuresTime frame: Day 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Bristol NHS Foundation Trust

    Bristol, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.